Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases

Lancet

Volumn 347, Issue 9012, 1996, Pages 1357-1361

  Gårdlund, Bengt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFECTION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM;

EID: 0029869085     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91009-0     Document Type: Article

References (34)

1. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318: 1162-73.
2. Gallus AS. Anticoagulants in the prevention of venous thromboembolism. Clin Haematol 1990; 3: 651-84.
3. Thromboembolic Risk Factors (THRIFT) Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. BMJ 1992; 305: 567-74.
4. Kakkar VV. Prevention of fatal pulmonary embolism. Haemostasis 1993; 23 (suppl 1): 42-50.
5. Green D, Hirsh J, Heit J, Prins M, Davidson B, Lensing AWA. Low molecular weight heparin: a critical analysis of clinical trials. Pharmacol Rev 1994; 46: 89-109.
6. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989; 82: 203-05.
7. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991; 302: 709-11.
8. Havig Ö. Pulmonary thromboembolism: clinicopathological correlations and multiple regression analysis of possible risk factors. Acta Chir Scand 1977; 478 (suppl): 48-80.
9. Saeger W, Genzkow M. Venous thromboses and pulmonary embolisms in post-mortem series: probable causes by correlations of clinical data and basic diseases. Pathol Res Pract 1994; 190: 394-99.
10. Coon WW, Coller FA. Some epidemiologic considerations of thromboembolism. Surg Gynecol Obstet 1959; 109: 487-501.
11. Gårdlund B. Fatal pulmonary embolism in hospitalized non-surgical patients. Acta Med Scand 1985; 218: 417-21.
12. Warlow C, Beattie AG, Terry G, Ogston D, Kenmure ACF, Douglas AS. A double-blind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. Lancet 1973; ii: 934-36.
13. Wray R, Maurer B, Shillingford J. Prophylactic anticoagulant therapy in the prevention of calf-vein thrombosis after myocardial infarction. N Engl J Med 1973; 288: 815-17.
14. McCarthy ST, Turner JJ, Robertson D, Hawkey CJ. Low-dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet 1977; ii: 800-01.
15. Emerson PA, Marks P. Preventing thromboembolism after myocardial infarction: effect of low-dose heparin or smoking. BMJ 1977; i: 18-20.
16. Pitt A, Anderson ST, Habersberger PG, Rosengarten DS. Low dose heparin in the prevention of deep-vein thromboses in patients with acute myocardial infarction. Am Heart J 1980; 99: 574-78.
17. Belch JJ, Lowe GDO, Ward AG, Forbes CD, Prentice CRM. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981; 26: 115-17.
18. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10: 448-50.
19. Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982; 96: 561-65.
20. Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986; 16: 159-64.
21. McCarthy ST, Turner J. Low-dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary emboli following acute stroke. Age Ageing 1986; 15: 84-88.
22. Turpie AGG, Levine MN, Hirsh J, et al. Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987; i: 523-26.
23. Hamilton MG, Hull RD, Pineo GF. Venous thromboembolism in neurosurgery and neurology patients: a review. Neurosurgery 1994; 34: 280-96.
24. Zelen M. A new design for randomized clinical trials. N Engl J Med 1979; 300: 1242-45.
25. Arcelus JI, Caprini JA, Traverse CI. Venous thromboembolism after hospital discharge. Semin Thromb Hemost 1993; 19 (suppl 1): 142-46.
26. Ginsberg JS, Kowalchuk G, Hirsh J, et al. Heparin effect on bone density. Thromb Haemost 1990; 64: 286-89.
27. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-35.
28. Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995; 89: 431-39.
29. National Institute of Health Consensus Conference. Prevention of venous thrombosis and pulmonary embolism. JAMA 1986; 256: 744-49.
30. European Consensus Statement. Prevention of venous thromboembolism. Int Angiol 1992; 11: 151-59.
31. Kakkar AK, Hedges AR, Williamson RCN, Kakkar VV. Perioperative heparin therapy inhibits late death from metastatic cancer. Int J Oncology 1995; 6: 885-89.
32. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-65.
33. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340: 152-56.
34. Hirsh J. Overview of low molecular weight heparins and heparinoids: basic and clinical aspects. Aust N Z J Med 1992; 22: 487-95.